Acute myeloid leukemia, MLL gene rearrangement
MONDO:0100404Any acute myeloid leukemia that has the chromosomal anomaly MLL gene rearrangement. (A molecular abnormality indicating rearrangement of the MLL (KMT2A) gene.)
Also known as: AML, KMT2A Gene Rearrangement, AML, KMT2A Rearrangement, AML, Lysine (K)-Specific Methyltransferase 2A Gene Rearrangement, AML, Lysine Methyltransferase 2A Gene Rearrangement, AML, MLL Rearrangement, AML, MLL gene rearrangement, AML, Mixed Lineage Leukaemia Gene Rearrangement, AML, Mixed Lineage Leukemia Gene Rearrangement
3114 clinical trials for this condition and its sub-types, 23 tagged with Acute myeloid leukemia, MLL gene rearrangement itself.
Follow this condition to get notified about new trialsWhere it sits in the disease tree
Browse by category →Part of
-
New Three-Drug cocktail aims to beat aggressive leukemia
Disease control Not yet recruitingThis study tests a new combination of three drugs—revumenib, azacitidine, and venetoclax—in people newly diagnosed with a specific, hard-to-treat leukemia called KMT2A-rearranged AML. The goal is to see if this cocktail can help more patients achieve remission with fewer side eff…
Phase 2 • Sponsor: UNC Lineberger Comprehensive Cancer Center • Aim: Disease control
Last updated Sep 12, 2026 00:00 UTC
-
Can a menin-blocking drug outsmart stubborn leukemia?
Disease control Not yet recruitingThis trial is testing an experimental drug called S243249, which blocks a protein called menin, in people whose acute leukemia has come back or not responded to standard treatment. The study focuses on patients with specific genetic changes (KMT2A or NUP98 translocations, or NPM1…
Phase 1/2 • Sponsor: Servier • Aim: Disease control
Last updated Sep 05, 2026 00:00 UTC
-
New drug combo targets tough leukemia in early trial
Disease control Not yet recruitingThis early-phase study tests two oral drugs, ziftomenib and mezigdomide, given together to adolescents and adults with acute myeloid leukemia (AML) that has come back or not responded to treatment. The trial focuses on people whose leukemia has specific genetic changes (KMT2A rea…
Phase 1 • Sponsor: Massachusetts General Hospital • Aim: Disease control
Last updated Jun 27, 2026 08:13 UTC